Acorai: Difference between revisions

From Research Wiki
Added valuation: ~€20-40M (€4.2M+ raised)
Added revenue from allabolag.se (org 559564-5069)
 
Line 10: Line 10:
== What They Do ==
== What They Do ==
Non-invasive intracardiac pressure monitor for heart failure management. The device measures pressure inside the heart without invasive catheterization, enabling continuous monitoring of heart failure patients.<ref>TechCrunch (2023): "Heart failure monitoring startup Acorai turns heads with oversubscribed seed"</ref>
Non-invasive intracardiac pressure monitor for heart failure management. The device measures pressure inside the heart without invasive catheterization, enabling continuous monitoring of heart failure patients.<ref>TechCrunch (2023): "Heart failure monitoring startup Acorai turns heads with oversubscribed seed"</ref>
== Revenue ==
'''Org nr:''' 559564-5069
'''Source:''' [N/A (no accounts filed) allabolag.se]
* '''2024:''' Pre-revenue
* '''Employees:''' 0
Non-invasive intracardiac pressure monitor. Pre-revenue. Limhamn.


== Funding ==
== Funding ==

Latest revision as of 08:09, 14 April 2026

Template:Company

What They Do[edit]

Non-invasive intracardiac pressure monitor for heart failure management. The device measures pressure inside the heart without invasive catheterization, enabling continuous monitoring of heart failure patients.[1]

Revenue[edit]

Org nr: 559564-5069 Source: [N/A (no accounts filed) allabolag.se]

  • 2024: Pre-revenue
  • Employees: 0

Non-invasive intracardiac pressure monitor. Pre-revenue. Limhamn.

Funding[edit]

Valuation: ~€20-40M (€4.2M+ raised)

  • €2.3M seed round[2]
  • €4.2M additional (December 2024), preparing to raise additional capital[3]

Regulatory[edit]

Received FDA Breakthrough Device Designation for their non-invasive intracardiac pressure monitor.[4] This designation accelerates the FDA review process for devices addressing unmet medical needs.

See Also[edit]

  1. TechCrunch (2023): "Heart failure monitoring startup Acorai turns heads with oversubscribed seed"
  2. MassDevice (2023): "Intracardiac pressure monitoring device startup Acorai raises €2.3M"
  3. Silicon Canals (Dec 2024): "Sweden's Acorai bags €4.2M to advance its heart failure management devices"
  4. PR Newswire (2024): "Acorai receives Breakthrough Device Designation for their non-invasive intracardiac pressure monitor"